This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
2mu9
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Changing ABRA protein peptide to fit the HLA-DR B1*0301 molecule renders it protection-inducing== | |
| + | <StructureSection load='2mu9' size='340' side='right' caption='[[2mu9]], [[NMR_Ensembles_of_Models | 21 NMR models]]' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[2mu9]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2MU9 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2MU9 FirstGlance]. <br> | ||
| + | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2mu9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2mu9 OCA], [http://pdbe.org/2mu9 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2mu9 RCSB], [http://www.ebi.ac.uk/pdbsum/2mu9 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=2mu9 ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | The Plasmodium falciparum acidic-basic repeat antigen represents a potential malarial vaccine candidate. One of this protein's high activity binding peptides, named 2150 ((161)KMNMLKENVDYIQKNQNLFK(180)), is conserved, non-immunogenic, and non-protection-inducing. Analogue peptides whose critical binding residues (in bold) were replaced by amino-acids having similar mass but different charge were synthesized and tested to try to modify such immunological properties. These analogues' HLA-DRbeta1* molecule binding ability were also studied in an attempt to explain their biological mechanisms and correlate binding capacity and immunological function with their three-dimensional structure determined by (1)H NMR. A 3(10) distorted helical structure was identified in protective and immunogenic peptide 24922 whilst alpha-helical structure was found for non-immunogenic, non-protective peptides having differences in alpha-helical position. The changes performed on immunogenic, protection-inducing peptide 24922 allowed it to bind specifically to the HLA-DRbeta1*0301 molecule, suggesting that these changes may lead to better interaction with the MHC Class II-peptide-TCR complex rendering it immunogenic and protective, thus suggesting a new way of developing multi-component, sub-unit-based anti-malarial vaccines. | ||
| - | + | Changing ABRA protein peptide to fit into the HLA-DRbeta1*0301 molecule renders it protection-inducing.,Salazar LM, Alba MP, Curtidor H, Bermudez A, Luis E Vargas, Rivera ZJ, Patarroyo ME Biochem Biophys Res Commun. 2004 Sep 10;322(1):119-25. PMID:15313182<ref>PMID:15313182</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | + | </div> | |
| - | + | <div class="pdbe-citations 2mu9" style="background-color:#fffaf0;"></div> | |
| - | + | == References == | |
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
[[Category: Alba, M]] | [[Category: Alba, M]] | ||
| - | [[Category: Salazar, L]] | ||
[[Category: Bermudez, A]] | [[Category: Bermudez, A]] | ||
| - | [[Category: Rivera, Z]] | ||
[[Category: Curtidor, H]] | [[Category: Curtidor, H]] | ||
| + | [[Category: Patarroyo, M]] | ||
| + | [[Category: Rivera, Z]] | ||
| + | [[Category: Salazar, L]] | ||
| + | [[Category: Vargas, L]] | ||
| + | [[Category: Peptide binding protein]] | ||
Revision as of 16:47, 16 November 2017
Changing ABRA protein peptide to fit the HLA-DR B1*0301 molecule renders it protection-inducing
| |||||||||||
